Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 5,400 shares of the business’s stock in a transaction on Tuesday, November 22nd. The shares were acquired at an average price of $10.28 per share, for a total transaction of $55,512.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $31,548,816.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, November 21st, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were acquired at an average price of $10.41 per share, for a total transaction of $37,476.00.
  • On Friday, November 18th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were acquired at an average price of $10.38 per share, for a total transaction of $18,684.00.
  • On Wednesday, November 16th, Phillip Md Et Al Frost bought 4,300 shares of Opko Health stock. The shares were purchased at an average price of $10.13 per share, for a total transaction of $43,559.00.
  • On Friday, November 11th, Phillip Md Et Al Frost bought 14,600 shares of Opko Health stock. The shares were purchased at an average price of $9.46 per share, for a total transaction of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The shares were purchased at an average price of $9.33 per share, for a total transaction of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost bought 23,100 shares of Opko Health stock. The shares were purchased at an average price of $9.22 per share, for a total transaction of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were purchased at an average price of $9.48 per share, for a total transaction of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were purchased at an average price of $9.49 per share, for a total transaction of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost bought 11,800 shares of Opko Health stock. The shares were purchased at an average price of $9.43 per share, for a total transaction of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were purchased at an average price of $9.46 per share, for a total transaction of $94,600.00.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at 10.70 on Friday. The firm’s market capitalization is $5.97 billion. The stock has a 50 day moving average price of $9.76 and a 200 day moving average price of $9.87. Opko Health Inc. has a 12-month low of $7.12 and a 12-month high of $11.85.

Opko Health (NASDAQ:OPK) last issued its earnings results on Monday, November 7th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The company earned $298 million during the quarter, compared to analyst estimates of $322 million. Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The business’s revenue was up 108.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.25 EPS. Equities analysts anticipate that Opko Health Inc. will post ($0.08) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

A number of analysts recently weighed in on OPK shares. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, October 25th. JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the company a “buy” rating in a report on Tuesday, August 9th. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Opko Health in a report on Monday, October 10th. Jefferies Group reaffirmed a “hold” rating and issued a $10.00 price target on shares of Opko Health in a report on Monday, October 10th. Finally, TheStreet downgraded Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, November 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $13.17.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Whalerock Point Partners LLC purchased a new position in shares of Opko Health during the third quarter valued at approximately $2,100,000. Piedmont Investment Advisors LLC purchased a new position in shares of Opko Health during the third quarter valued at approximately $622,000. Price T Rowe Associates Inc. MD raised its position in shares of Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock valued at $10,038,000 after buying an additional 28,700 shares during the last quarter. Finally, LPL Financial LLC raised its position in shares of Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock valued at $142,000 after buying an additional 504 shares during the last quarter. Institutional investors own 20.33% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Phillip Md Et Al Frost Purchases 5,400 Shares of Opko Health Inc. (OPK) Stock” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/25/phillip-md-et-al-frost-purchases-5400-shares-of-opko-health-inc-opk-stock.html.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.